Dana Murdock

Regeneron Pharmaceuticals

Poster(s):

• (A-188) Group-Based Trajectory Models to Identify Potential Reasons for Treatment Switch Among Patients with Neovascular Age-Related Macular Degeneration (nAMD)
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (C-197) Prevalence of congenital and acquired generalized lipodystrophy in the EU
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (B-016) Trends in the Incidence of Monoclonal Gammopathy of Undetermined Significance (MGUS) Before and During the COVID-19 Pandemic
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET